Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few therapeutic options. Recent advances in this field brought about new perspectives in the treatment of this disease. Molecular, basic, and translational research has gi...
Saved in:
| Main Authors: | Teresa Maria Santos Amaral, Daniela Macedo, Isabel Fernandes, Luis Costa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2012/327253 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01) -
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
by: Alexander W Wyatt, et al.
Published: (2015-04-01) -
New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01) -
Role of exosomes in castration-resistant prostate cancer
by: Yuan Cao, et al.
Published: (2025-05-01) -
Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01)